The KidneyIntelX uses machine learning algorithms to analyze predictive blood-based biomarkers and information from a patient’s EHR to detect kidney disease, then provide information to improve the clinical management of the disease. The device specifically caters to patients with Type 2 diabetes, who have an elevated risk of developing kidney disease.
“Breakthrough Device” status does not guarantee FDA approval, but it does acknowledge a medical device’s potential in the diagnosis or treatment of debilitating and life-threatening diseases. Devices with this designation are expedited through the FDA’s assessment and review process in an effort to give patients and healthcare providers access to them as soon as possible.
More articles about AI:
Novartis, Pfizer, Centene CEOs on AI’s limitations in healthcare
FDA exploring use of AI, blockchain to monitor food safety
Accenture uses Google AI to combat loneliness in aging population
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.